-
1.发明授权Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof 失效可用于降低淀粉样蛋白前体蛋白和治疗痴呆的药剂及其使用方法公开(公告)号：US08691864B2
公开(公告)日：2014-04-08
申请号：US13559186
申请日：2012-07-26
申请人： Nigel H. Greig , Karen T. Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane M. Davidson , Michael Sturgess
发明人： Nigel H. Greig , Karen T. Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane M. Davidson , Michael Sturgess
IPC分类号： A61K31/40
CPC分类号： C07D487/04 , A61K31/325 , A61K31/343 , A61K31/345 , A61K31/381 , A61K31/382 , A61K31/403 , A61K31/405 , A61K31/407 , C07D209/16 , C07D209/34 , C07D209/36 , C07D209/38 , C07D277/82 , C07D453/04 , C07D471/04 , C07D487/08 , C07D491/04 , C07D495/04
摘要： The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.
摘要翻译： 本发明提供了向受试者施用化合物和方法，所述方法可以减少和产生APP，并且在广泛的剂量范围内是无毒的。 本发明还提供了非氨基甲酸酯化合物和向受试者施用此类化合物的方法，所述方法可以减少APP生产并且在广泛剂量范围内不具有毒性。 已经发现外消旋或对映体纯的非氨基甲酸酯化合物可用于减少和生产APP生产。
-
2.发明授权Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof 有权可用于降低淀粉样蛋白前体蛋白和治疗痴呆的药剂及其使用方法公开(公告)号：US08258172B2
公开(公告)日：2012-09-04
申请号：US12841888
申请日：2010-07-22
申请人： Nigel H. Greig , Karen T. Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane M. Davidson , Michael Sturgess
发明人： Nigel H. Greig , Karen T. Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane M. Davidson , Michael Sturgess
IPC分类号： A61K31/40
CPC分类号： C07D487/04 , A61K31/325 , A61K31/343 , A61K31/345 , A61K31/381 , A61K31/382 , A61K31/403 , A61K31/405 , A61K31/407 , C07D209/16 , C07D209/34 , C07D209/36 , C07D209/38 , C07D277/82 , C07D453/04 , C07D471/04 , C07D487/08 , C07D491/04 , C07D495/04
摘要： The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.
摘要翻译： 本发明提供了向受试者施用化合物和方法，所述方法可以减少和产生APP，并且在广泛的剂量范围内是无毒的。 本发明还提供了非氨基甲酸酯化合物和向受试者施用此类化合物的方法，所述方法可以减少APP生产并且在广泛剂量范围内不具有毒性。 已经发现外消旋或对映体纯的非氨基甲酸酯化合物可用于减少和生产APP生产。
-
3.发明授权Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof 有权可用于降低淀粉样蛋白前体蛋白和治疗痴呆的药剂及其使用方法公开(公告)号：US07786162B2
公开(公告)日：2010-08-31
申请号：US12357115
申请日：2009-01-21
申请人： Nigel H. Greig , Karen T. Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane M. Davidson , Michael Sturgess
发明人： Nigel H. Greig , Karen T. Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane M. Davidson , Michael Sturgess
IPC分类号： A61K31/40 , C07D487/00
CPC分类号： C07D487/04 , A61K31/325 , A61K31/343 , A61K31/345 , A61K31/381 , A61K31/382 , A61K31/403 , A61K31/405 , A61K31/407 , C07D209/16 , C07D209/34 , C07D209/36 , C07D209/38 , C07D277/82 , C07D453/04 , C07D471/04 , C07D487/08 , C07D491/04 , C07D495/04
摘要： The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.
摘要翻译： 本发明提供了向受试者施用化合物和方法，所述方法可以减少和产生APP，并且在广泛的剂量范围内是无毒的。 本发明还提供了非氨基甲酸酯化合物和向受试者施用此类化合物的方法，所述方法可以减少APP生产并且在广泛剂量范围内不具有毒性。 已经发现外消旋或对映体纯的非氨基甲酸酯化合物可用于减少和生产APP生产。
-
4.发明申请Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof 失效可用于降低淀粉样蛋白前体蛋白和治疗痴呆的药剂及其使用方法公开(公告)号：US20120295946A1
公开(公告)日：2012-11-22
申请号：US13559186
申请日：2012-07-26
申请人： Nigel H. Greig , Karen T.Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane M. Davidson , Michael Sturgess
发明人： Nigel H. Greig , Karen T.Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane M. Davidson , Michael Sturgess
IPC分类号： A61K31/407 , A61P25/28
CPC分类号： C07D487/04 , A61K31/325 , A61K31/343 , A61K31/345 , A61K31/381 , A61K31/382 , A61K31/403 , A61K31/405 , A61K31/407 , C07D209/16 , C07D209/34 , C07D209/36 , C07D209/38 , C07D277/82 , C07D453/04 , C07D471/04 , C07D487/08 , C07D491/04 , C07D495/04
摘要： The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.
摘要翻译： 本发明提供了向受试者施用化合物和方法，所述方法可以减少和产生APP，并且在广泛的剂量范围内是无毒的。 本发明还提供了非氨基甲酸酯化合物和向受试者施用此类化合物的方法，所述方法可以减少APP生产并且在广泛剂量范围内不具有毒性。 已经发现外消旋或对映体纯的非氨基甲酸酯化合物可用于减少和生产APP生产。
-
5.发明申请Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof 有权可用于降低淀粉样蛋白前体蛋白和治疗痴呆的药剂及其使用方法公开(公告)号：US20110021594A1
公开(公告)日：2011-01-27
申请号：US12841888
申请日：2010-07-22
申请人： Nigel H. Greig , Karen T.Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane Davidson , Michael Sturgess
发明人： Nigel H. Greig , Karen T.Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane Davidson , Michael Sturgess
IPC分类号： A61K31/407 , A61P25/28
CPC分类号： C07D487/04 , A61K31/325 , A61K31/343 , A61K31/345 , A61K31/381 , A61K31/382 , A61K31/403 , A61K31/405 , A61K31/407 , C07D209/16 , C07D209/34 , C07D209/36 , C07D209/38 , C07D277/82 , C07D453/04 , C07D471/04 , C07D487/08 , C07D491/04 , C07D495/04
摘要： The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.
摘要翻译： 本发明提供了向受试者施用化合物和方法，所述方法可以减少和产生APP，并且在广泛的剂量范围内是无毒的。 本发明还提供了非氨基甲酸酯化合物和向受试者施用此类化合物的方法，所述方法可以减少APP生产并且在广泛剂量范围内不具有毒性。 已经发现外消旋或对映体纯的非氨基甲酸酯化合物可用于减少和生产APP生产。
-
6.发明申请Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof 有权可用于降低淀粉样蛋白前体蛋白和治疗痴呆的药剂及其使用方法公开(公告)号：US20090131501A1
公开(公告)日：2009-05-21
申请号：US12357115
申请日：2009-01-21
申请人： Nigel H. Greig , Karen T.Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane Davidson , Michael Sturgess
发明人： Nigel H. Greig , Karen T.Y. Shaw , Qiang-Sheng Yu , Harold W. Holloway , Tada Utsuki , Timothy T. Soncrant , Donald K. Ingram , Arnold Brossi , Anthony Giordano , Gordon Powers , Diane Davidson , Michael Sturgess
IPC分类号： A61K31/407 , A61P25/28
CPC分类号： C07D487/04 , A61K31/325 , A61K31/343 , A61K31/345 , A61K31/381 , A61K31/382 , A61K31/403 , A61K31/405 , A61K31/407 , C07D209/16 , C07D209/34 , C07D209/36 , C07D209/38 , C07D277/82 , C07D453/04 , C07D471/04 , C07D487/08 , C07D491/04 , C07D495/04
摘要： The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.
摘要翻译： 本发明提供了向受试者施用可以降低βAPP产生并且在广泛剂量范围内无毒性的化合物和方法。 本发明还提供了非氨基甲酸酯化合物和向可以减少βAPP产生并且在广泛剂量范围内无毒性的受试者施用此类化合物的方法。 已经发现外消旋或对映异构体纯的非氨基甲酸酯化合物可用于降低βAPP产生。
-
公开(公告)号：US5409948A
公开(公告)日：1995-04-25
申请号：US980399
申请日：1992-11-23
申请人： Nigel H. Greig , Arnold Brossi , Timothy T. Soncrant , Harold W. Holloway , Stanley I. Rapoport , Setsu Iijima , Edward L. Spangler , Donald K. Ingram , Xue F. Pei
发明人： Nigel H. Greig , Arnold Brossi , Timothy T. Soncrant , Harold W. Holloway , Stanley I. Rapoport , Setsu Iijima , Edward L. Spangler , Donald K. Ingram , Xue F. Pei
IPC分类号： C07D487/04 , A61K31/40 , A61P25/28
CPC分类号： A61K31/40
摘要： An improved method of cholinomimetic therapy for cognitive impairments associated with aging and Alzheimer's disease comprising treating a patient with an effective amount of phenserine or a pharmaceutically acceptable salt and derivatives.
摘要翻译： 一种用于与老化和阿尔茨海默氏病相关的认知障碍的改善的胆碱模拟治疗方法，其包括用有效量的苯丝氨酸或其药学上可接受的盐和衍生物治疗患者。
-
8.发明授权Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias 失效用于治疗和诊断阿尔茨海默氏病和痴呆症的高选择性丁酰胆碱酯酶抑制剂公开(公告)号：US06683105B2
公开(公告)日：2004-01-27
申请号：US10071488
申请日：2002-02-07
IPC分类号： C07D48704
CPC分类号： A61K31/40 , A61K31/407 , C07D487/04 , C07D491/048 , C07D495/14
摘要： A method for treating cognitive impairments associated with aging or Alzheimer's disease which comprises treating a patient at risk for having the cognitive impairment with an effective amount of a highly selective butyrylcholinesterase inhibitor which is N8-benzylnorcymserine, N1-phenethylnorcymserine, N1, N8-bisnorcymserine, N1-N8-bisbenzylnorphysostigmine, N1, N8-bisbenzylnorphenserine, N1, N8-bisbenzylnorcymserine, or pharmaceutical acceptable salts thereof.
摘要翻译： 一种用于治疗与衰老或阿尔茨海默氏病相关的认知障碍的方法，其包括用有效量的高选择性丁酰胆碱酯酶抑制剂治疗具有认知障碍风险的患者，所述高度选择性丁酰胆碱酯酶抑制剂是N 8 - 苄基乳清丝氨酸，N，N-苯基氨基丝氨酸， N 1，N 8 - 双氰胺丝氨酸，N 1 -N 8 - 双苯基吗啉青霉素，N 1，N 8 - 苄基苯丙氨酸，N 1，N 8 - 苄基氰尿素或药物 其可接受的盐。
-
9.发明授权Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias 有权用于治疗和诊断阿尔茨海默氏病和痴呆症的高选择性丁酰胆碱酯酶抑制剂公开(公告)号：US06410747B1
公开(公告)日：2002-06-25
申请号：US09254494
申请日：1999-06-17
IPC分类号： C07D48704
CPC分类号： A61K31/40 , A61K31/407 , C07D487/04 , C07D491/048 , C07D495/14
摘要： A method for preventing or treating cognitive impairments associated with aging or Alzheimer's disease which comprises treating a patient at risk for having the cognitive impairment with an effective amount of a highly selective butyrylcholinesterase inhibitor.
摘要翻译： 一种用于预防或治疗与衰老或阿尔茨海默氏病相关的认知障碍的方法，其包括用有效量的高选择性丁酰胆碱酯酶抑制剂治疗具有认知障碍风险的患者。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.049 秒)
